Opendata, web and dolomites

SYN1002

A New Therapeutic Option to Protect Central Nervous System against Acute Ischemic Stroke

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SYN1002 project word cloud

Explore the words cloud of the SYN1002 project. It provides you a very rough idea of what is the project "SYN1002" about.

of    preclinical    thrombolytic    feasibility    larger    auto    framework    millions    treat    approved    stoke    share    treatment    applicable    billion    confirming    institutes    window    patient    stage    iia    net    doses    million    substance    experiencing    plan    agent    realize    causing    265m    initially    pharmaceutical    perfect    search    pioneer    acute    syn1002    2017    safety    patients    2026       market    ischemic    sales    indication    suitable    event    permanent    potent    peptide    protect    business    match    recombinant    suffering    orphit    2012    ongoing    anti    16    strokes    time    seed    drug    tolerability    disability    biotech    tissue    neuroprotective    safe    multiple    deal    neuronal    health    limited    proof    clinical    treatments    six    markets    therapeutic    each    deaths    activator    plasminogen    50    qualify    pathologies    licensing    immune    damage    successfully    ais    400m    inflammatory    draw    efficient    persons    intends    world    documenting    rtpa    administered    complement    positioning    solution    peak    stroke    company    industry   

Project "SYN1002" data sheet

The following table provides information about the project.

Coordinator
ORPHIT 

Organization address
address: 1093 CHEMIN DES PLATEAUX FLEURIS RESIDENCES PANORA LA B
city: SAINT-LAURENT-DU-VAR
postcode: 6700
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.orphitpharma.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-08-01   to  2018-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ORPHIT FR (SAINT-LAURENT-DU-VAR) coordinator 50˙000.00

Map

 Project objective

Each year, about 16 million strokes occur in the world causing millions of deaths and one third of patients experiencing permanent disability. The main treatment of stroke is thrombolytic agent recombinant tissue plasminogen activator (rtPA). Not all the patient can qualify for this treatment and it can be administered only in a limited time window. No existing drug is approved to protect against ongoing neuronal damage after the acute event. In this framework, our company, ORPHIT, a seed-stage biotech company, intends to be a pioneer by bringing clinical proof of concept of our peptide SYN1002 as suitable neuroprotective anti-inflammatory agent to treat stoke in acute phase that could be administered at multiple doses as complement to current thrombolytic treatments and also in patients who do not qualify for treatment with rtPA. This peptide is our lead product and has been initially developed as a potent anti-inflammatory substance in auto-immune pathologies with a clinical phase 1 study successfully documenting the safety and tolerability. Its properties make it a perfect match with current needs on Stroke treatment. Therefore, our solution is of interest for the pharmaceutical industry and health institutes who are currently in the search of a treatment that would be efficient and safe enough to be applicable to a larger part of the persons suffering from Stroke. The acute ischemic stroke (AIS) therapeutic market generated 400M€ in 2012 across the six major markets and is expected to reach 1.1 billion € by the end of 2017. SYN1002 sales at peak (2026) are expected to achieve 50% of market share, and a licensing deal at end of phase IIa would come out with a net present value of 265M€ for our company. In order to achieve this goal ORPHIT will realize a feasibility study aiming at strengthening SYN1002 preclinical package in AIS indication, confirming drug positioning through in depth market study, and draw a European business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYN1002" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYN1002" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More